Maverick Therapeutics

Maverick Therapeutics is establishing itself as the leader in the race to apply T-cell therapy to solid tumor cancers by focusing deep integrated expertise in drug development to design and deliver a pioneering immunotherapy platform. Maverick's highly innovative COBRA™ therapeutic platform is the most mature, conditionally active bispecific T-cell engaging platform designed to eliminate solid tumors. With COBRA, T-cell activation and resulting cell killing only take place where it is needed - in tumors. This unique design delivers the long sought trifecta in cancer care; high specificity, high potency and reduced toxicity. Founded in 2016, Maverick is led by a team of leading experts in protein engineering and T-cell therapeutic research and development. Prior to acquisition, Maverick was funded by Takeda, MPM BioVentures 2014 and MPM Capital's UBS Oncology Impact Fund.